2022
Evaluation of the Pfs25-IMX313/Matrix-M malaria transmission-blocking candidate vaccine in endemic settings
Mulamba C, Williams C, Kreppel K, Ouedraogo J, Olotu A. Evaluation of the Pfs25-IMX313/Matrix-M malaria transmission-blocking candidate vaccine in endemic settings. Malaria Journal 2022, 21: 159. PMID: 35655174, PMCID: PMC9161629, DOI: 10.1186/s12936-022-04173-y.Peer-Reviewed Original ResearchConceptsEndemic settingsMalaria transmission-blocking vaccineHuman vaccine trialsTransmission-blocking vaccinesPublic health importanceMosquito vectorsMiddle-income settingsAnti-malarial drugsImmunological mechanismsCandidate vaccinesVaccine trialsHealthy individualsIncome settingsTransmission blockingHealth importanceMalaria controlMalaria parasitesVaccineLocal interventionsDrugsInterventionSettingSexual stagesPfs25Disease
2014
The impact of clinical research activities on communities in rural Africa: the development of the Clinical Research Unit of Nanoro (CRUN) in Burkina Faso
Tinto H, Valea I, Sorgho H, Tahita M, Traore M, Bihoun B, Guiraud I, Kpoda H, Rouamba J, Ouédraogo S, Lompo P, Yara S, Kabore W, Ouédraogo J, Guiguemdé R, Binka F, Ogutu B. The impact of clinical research activities on communities in rural Africa: the development of the Clinical Research Unit of Nanoro (CRUN) in Burkina Faso. Malaria Journal 2014, 13: 113. PMID: 24655351, PMCID: PMC3994337, DOI: 10.1186/1475-2875-13-113.Peer-Reviewed Original ResearchConceptsClinical research unitMalaria vaccine trialsClinical trial platformDemographic Surveillance SystemResource-poor settingsClinical research activitiesClinical laboratory servicesVaccine trialsHealth workersNanoroMalaria controlClinical researchNew drugsTrial platformHealth careLaboratory servicesResearch UnitSurveillance systemSaharan AfricaStudy dataTotal populationRural AfricaActive advocacyBurkina FasoPopulation
1990
Vaccination against malaria: initial trial with an ant-sporozoite vaccine, (NANP)3-TT (RO 40-2361) in Africa (Bobo-Dioulasso, Burkina Faso).
Guiguemdé T, Sturchler D, Ouédraogo J, Drabo M, Etlinger H, Douchet C, Gbary A, Haller L, Kambou S, Fernex M. Vaccination against malaria: initial trial with an ant-sporozoite vaccine, (NANP)3-TT (RO 40-2361) in Africa (Bobo-Dioulasso, Burkina Faso). Bulletin De La Société De Pathologie Exotique 1990, 83: 217-27. PMID: 2119897.Peer-Reviewed Original ResearchConceptsDoses of TTAntibody titresCircumsporozoite proteinAverage antibody titresPeak IgG responseMonths of ageClinical malariaIgG responsesSystemic reactionsProtective efficacyVaccine trialsImmunological statusImmunisation vaccinesTetanus toxoidProtective effectGroup IIMalaria transmissionDay 0VaccineGroup IGroup IIIPlasmodium falciparumDay 75MalariaDay 150